Gilead Sciences Inc. (NASDAQ:GILD) – Leerink Swann reduced their Q3 2016 earnings per share estimates for Gilead Sciences in a research note issued on Tuesday. Leerink Swann analyst G. Porges now expects that the firm will post earnings of $2.91 per share for the quarter, down from their prior forecast of $2.95. Leerink Swann currently has a “Market Perform” rating and a $94.00 price target on the stock. Leerink Swann also issued estimates for Gilead Sciences’ FY2016 earnings at $11.89 EPS, FY2017 earnings at $11.12 EPS, FY2018 earnings at $10.66 EPS, FY2019 earnings at $10.63 EPS and FY2020 earnings at $11.33 EPS.
Several other equities analysts have also recently commented on the stock. Piper Jaffray Cos. restated a “buy” rating and issued a $108.00 target price on shares of Gilead Sciences in a research report on Monday, August 15th. Jefferies Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $76.89 to $91.00 in a research report on Tuesday, September 6th. Morgan Stanley restated a “hold” rating and issued a $103.00 target price on shares of Gilead Sciences in a research report on Wednesday, June 15th. Berenberg Bank initiated coverage on shares of Gilead Sciences in a research report on Thursday, September 22nd. They issued a “buy” rating for the company. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Sunday, July 10th. Eleven equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $104.34.
Gilead Sciences (NASDAQ:GILD) opened at 77.86 on Thursday. The company has a market capitalization of $102.75 billion, a PE ratio of 6.83 and a beta of 1.06. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11. The firm has a 50-day moving average of $79.41 and a 200-day moving average of $85.61.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period last year, the firm earned $3.15 earnings per share. The business’s revenue for the quarter was down 5.7% on a year-over-year basis.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.41%. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now owns 132,964 shares in the company, valued at $10,881,773.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Milligan sold 112,000 shares of the stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the transaction, the chief executive officer now owns 1,170,963 shares of the company’s stock, valued at approximately $98,747,309.79. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Institutional investors have recently modified their holdings of the company. CWM LLC raised its position in shares of Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 17 shares in the last quarter. Cadence Bank NA raised its position in shares of Gilead Sciences by 0.8% in the second quarter. Cadence Bank NA now owns 3,727 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 28 shares in the last quarter. Marble Harbor Investment Counsel LLC raised its position in shares of Gilead Sciences by 0.9% in the second quarter. Marble Harbor Investment Counsel LLC now owns 3,330 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 30 shares in the last quarter. Birch Hill Investment Advisors LLC raised its position in shares of Gilead Sciences by 0.9% in the second quarter. Birch Hill Investment Advisors LLC now owns 3,336 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 30 shares in the last quarter. Finally, Blume Capital Management Inc. raised its position in shares of Gilead Sciences by 0.9% in the second quarter. Blume Capital Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $459,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 77.94% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.